325 related articles for article (PubMed ID: 24250310)
21. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Capurro M; Wanless IR; Sherman M; Deboer G; Shi W; Miyoshi E; Filmus J
Gastroenterology; 2003 Jul; 125(1):89-97. PubMed ID: 12851874
[TBL] [Abstract][Full Text] [Related]
22. Associated measurement of fucosylated levels of AFP, DCP, and GPC3 for early diagnosis in hepatocellular carcinoma.
Wu M; Liu Z; Zhang A; Li N
Int J Biol Markers; 2019 Mar; 34(1):20-26. PubMed ID: 30854929
[TBL] [Abstract][Full Text] [Related]
23. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
24. Can Glypican3 be diagnostic for early hepatocellular carcinoma among Egyptian patients?
Abdelgawad IA; Mossallam GI; Radwan NH; Elzawahry HM; Elhifnawy NM
Asian Pac J Cancer Prev; 2013; 14(12):7345-9. PubMed ID: 24460300
[TBL] [Abstract][Full Text] [Related]
25. Search for Effective Serum Tumor Markers for Early Diagnosis of Hepatocellular Carcinoma Associated with Hepatitis C.
Malov SI; Malov IV; Kuvshinov AG; Marche PN; Decaens T; Macek-Jilkova Z; Yushchuk ND
Sovrem Tekhnologii Med; 2021; 13(1):27-33. PubMed ID: 34513063
[TBL] [Abstract][Full Text] [Related]
26. Comparing the diagnostic value of serum oligosaccharide chain (G-test) and alpha-fetoprotein for hepatitis B virus-related liver cancer.
Wan L; Guo L; Hu Y; Huang H; Zhang M; Xu K; De G; Zheng F; Wu Z; Hu C; Wen Z
Clin Biochem; 2021 Mar; 89():44-50. PubMed ID: 33309517
[TBL] [Abstract][Full Text] [Related]
27. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
28. The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.
Leerapun A; Suravarapu SV; Bida JP; Clark RJ; Sanders EL; Mettler TA; Stadheim LM; Aderca I; Moser CD; Nagorney DM; LaRusso NF; de Groen PC; Menon KV; Lazaridis KN; Gores GJ; Charlton MR; Roberts RO; Therneau TM; Katzmann JA; Roberts LR
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):394-402; quiz 267. PubMed ID: 17368240
[TBL] [Abstract][Full Text] [Related]
29. AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease.
Beale G; Chattopadhyay D; Gray J; Stewart S; Hudson M; Day C; Trerotoli P; Giannelli G; Manas D; Reeves H
BMC Cancer; 2008 Jul; 8():200. PubMed ID: 18638391
[TBL] [Abstract][Full Text] [Related]
30. [The clinical value of serum GPC3 level in predicting recurrence of patients with primary hepatocellular carcinoma].
Zhang PR; Ma XL; Guo L; Lu RQ
Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Jun; 57(6):885-890. PubMed ID: 37357208
[No Abstract] [Full Text] [Related]
31. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
32. Development of a clinical chemiluminescent immunoassay for serum GPC3 and simultaneous measurements alone with AFP and CK19 in diagnosis of hepatocellular carcinoma.
Yu JP; Xu XG; Ma RJ; Qin SN; Wang CR; Wang XB; Li M; Li MS; Ma Q; Xu WW
J Clin Lab Anal; 2015 Mar; 29(2):85-93. PubMed ID: 24687454
[TBL] [Abstract][Full Text] [Related]
33. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
34. Liver Stiffness and Serum Alpha-Fetoprotein in Discriminating Small Hepatocellular Carcinoma from Cirrhotic Nodule.
Li JW; Ling WW; Lu Q; Lu CL; He D; Luo Y
Ultrasound Q; 2016 Dec; 32(4):319-326. PubMed ID: 27575844
[TBL] [Abstract][Full Text] [Related]
35. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
[TBL] [Abstract][Full Text] [Related]
36. Correlation between HBV protein preS2 and tumor markers of hepatocellular carcinoma.
Luan F; Liu B; Zhang J; Cheng S; Zhang B; Wang Y
Pathol Res Pract; 2017 Sep; 213(9):1037-1042. PubMed ID: 28869105
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
38. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
Wong RJ; Ahmed A; Gish RG
Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
[TBL] [Abstract][Full Text] [Related]
39. Combination of inflammatory score/liver function and AFP improves the diagnostic accuracy of HBV-related hepatocellular carcinoma.
Ding Y; Liu K; Xu Y; Zhao Q; Lou S; Xiang X; Yan L; Cao Z; Xie Q; Zhu C; Bao S; Wang H
Cancer Med; 2020 May; 9(9):3057-3069. PubMed ID: 32150664
[TBL] [Abstract][Full Text] [Related]
40. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]